Table 1.

Characteristics of enrolled patients (N = 121).

Age (Median, IQR)	61 (25–88)
Gender M F	74 (61%) 47 (39%)
Age ≤ 25 (%)	5 (4%)
Gender M F	4 (80%) 1 (20%)
Time period between transplantation and COVID-19 vaccination (months), median (IQR)	108 (12–384)
Duration of post-vaccination follow-up (months), median (IQR)	5 (3–9)
Immunosuppressive therapy at the time of enrollment Tacrolimus-Mycophenolate-Steroids Tacrolimus-Everolimus-Steroids Cyclosporine-Mycophenolate-Steroids Other immunosuppressive therapies	35 (29%) 10 (8%) 9 (7.5%) 67 (55.5%)
Incidence SARS-CoV-2 breakthrough Infection	18 (14.9%)
Ig anti-SARS-CoV-2 titer (BAU/mL) Pre-vaccination Positive 20 days after the first dose Positive 40 days after the second dose	0   5 (4.1%) 62 (51%)